Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer

Figures & data

Table 1. Phase 2/3 randomised, controlled HIPEC trials.

Clinicaltrials.gov dentifier	Sponsor	Condition	Intervention	HIPEC regimen	Status
NCT02681432	Hospital General de Ciudad Real University of Castilla-La Mancha, Spain	Primary or recurrent epithelial ovarian carcinoma (Stage II or higher)	Cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Paclitaxel 175 mg/m^2 for 60 min at 42–43°	Recruiting
NCT01539785	Catholic University of the Sacred Heart	Recurrent, platinum-sensitive ovarian cancer	Secondary cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Cisplatin 75 mg/m^2 for 60 min at 41–42.5°	Recruiting
NCT01091636	National Cancer Centre, Korea	Primary ovarian, tubal, and peritoneal cancers (Stage III or higher)	Cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Cisplatin 75 mg/m^2 for 90 min at 41.5°	Enrolling by invitation
NCT02124421	Mercy Medical Centre	Primary ovarian, tubal, and peritoneal cancers (Stage III or higher)	Cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Carboplatin AUC = 6	Recruiting
NCT01628380	A.O. Ospedale Papa Giovanni XXIII	Stage IIIC unresectable epithelial tubal/ovarian cancer with partial or complete response after 3 cycles of 1st-line chemotherapy	Interval cytoreductive surgery followed by HIPEC	Cisplatin 100 mg/m^2 and Paclitaxel 175 mg/m^2 for 90 min at 42°	Recruiting
NCT00426257	The Netherlands Cancer Institute	Stage III ovarian, peritoneal, or tubal carcinoma patients eligible for interval debulking surgery either following primary chemotherapy or following incomplete primary debulking and chemotherapy	Interval cytoreductive surgery followed by HIPEC	Cisplatin 100 mg/m^2	Ongoing, not recruiting
NCT01588964	Catholic University of the Sacred Heart	Recurrent, platinum-sensitive ovarian cancer	Secondary cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Oxaliplatin 460 mg/m^2 at 42°	Completed
NCT01376752	UNICANCER	Recurrent, platinum-sensitive ovarian carcinoma with peritoneal disease only after platinum-based second-line chemotherapy	Cytoreductive surgery followed by HIPEC	Cisplatin 75 mg/m^2 for 60 min	Recruiting
NCT01767675	Memorial Sloan Kettering Cancer Centre	Recurrent platinum-sensitive ovarian, tubal, or peritoneal cancer	Secondary cytoreductive surgery followed by HIPEC, adjuvant chemotherapy	Carboplatin 800 mg/m^2 for 90 min at 41–43°	Recruiting
NCT02567253	University Hospital, Ghent	Primary or recurrent platinum-sensitive serous epithelial ovarian or peritoneal carcinoma	Cytoreductive surgery followed by normothermic or hyperthermic IP chemotherapy	Cisplatin 75 or 120 mg/m^2 for 90 min at 37° or 41°	Recruiting
NCT02328716	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	Peritoneal carcinomatosis arising from primary or platinum-sensitive recurrent ovarian, peritoneal, or tubal carcinoma (Stage III or higher)	Cytoreductive surgery followed by HIPEC	Cisplatin	Ongoing, not recruiting

HIPEC: hyperthermic intraoperative intraperitoneal chemotherapy; AUC: area under the curve.